UBS Group’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $25.4M | Sell |
86,000
-15,700
| -15% | -$4.66M | ﹤0.01% | 2338 |
|
|
2025
Q4 | $27.8M | Hold |
101,700
| – | – | ﹤0.01% | 2258 |
|
|
2025
Q3 | $27.5M | Sell |
101,700
-1,200
| -1% | -$327K | ﹤0.01% | 2224 |
|
|
2025
Q2 | $28.4M | Buy |
102,900
+26,200
| +34% | +$7.12M | ﹤0.01% | 2027 |
|
|
2025
Q1 | $20.3M | Buy |
76,700
+55,200
| +257% | +$13.6M | ﹤0.01% | 2304 |
|
|
2024
Q4 | $4.99M | Hold |
21,500
| – | – | ﹤0.01% | 3851 |
|
|
2024
Q3 | $4.74M | Hold |
21,500
| – | – | ﹤0.01% | 3128 |
|
|
2024
Q2 | $4.23M | Sell |
21,500
-113,000
| -84% | -$23.3M | ﹤0.01% | 3033 |
|
|
2024
Q1 | $29M | Sell |
134,500
-208,100
| -61% | -$43.7M | 0.01% | 1411 |
|
|
2023
Q4 | $72.2M | Hold |
342,600
| – | – | 0.02% | 757 |
|
|
2023
Q3 | $68.6M | Buy |
342,600
+64,600
| +23% | +$12.8M | 0.02% | 665 |
|
|
2023
Q2 | $51.5M | Sell |
278,000
-6,100
| -2% | -$1.13M | 0.02% | 815 |
|
|
2023
Q1 | $54.4M | Buy |
284,100
+16,800
| +6% | +$3.04M | 0.02% | 733 |
|
|
2022
Q4 | $44.9M | Sell |
267,300
-28,300
| -10% | -$4.92M | 0.02% | 865 |
|
|
2022
Q3 | $52.4M | Buy |
295,600
+55,300
| +23% | +$10.9M | 0.02% | 668 |
|
|
2022
Q2 | $49.2M | Buy |
240,300
+8,900
| +4% | +$1.89M | 0.02% | 742 |
|
|
2022
Q1 | $55M | Sell |
231,400
-246,200
| -52% | -$57.8M | 0.02% | 786 |
|
|
2021
Q4 | $109M | Buy |
477,600
+97,853
| +26% | +$21.5M | 0.03% | 558 |
|
|
2021
Q3 | $73.4M | Buy |
379,747
+118,400
| +45% | +$24M | 0.02% | 668 |
|
|
2021
Q2 | $55.6M | Buy |
261,347
+82,639
| +46% | +$17.4M | 0.02% | 794 |
|
|
2021
Q1 | $36.5M | Sell |
178,708
-101,292
| -36% | -$20M | 0.01% | 1033 |
|
|
2020
Q4 | $51M | Buy |
280,000
+270,000
| +2,700% | +$45.9M | 0.02% | 773 |
|
|
2020
Q3 | $1.67M | Hold |
10,000
| – | – | ﹤0.01% | 3217 |
|
|
2020
Q2 | $1.63M | Hold |
10,000
| – | – | ﹤0.01% | 3070 |
|
|
2020
Q1 | $1.73M | Buy |
+10,000
| New | +$1.99M | ﹤0.01% | 2890 |
|
|
2019
Q4 | – | Sell |
-3,000
| Closed | -$634K | – | 8131 |
|
|
2019
Q3 | $634K | Buy |
+3,000
| New | +$627K | ﹤0.01% | 4355 |
|
|
2019
Q2 | – | Sell |
-25,000
| Closed | -$4.12M | – | 7884 |
|
|
2019
Q1 | $4.12M | Buy |
+25,000
| New | +$4.42M | ﹤0.01% | 2365 |
|
|
2018
Q4 | – | Sell |
-4,100
| Closed | -$698K | – | 8050 |
|
|
2018
Q3 | $698K | Buy |
+4,100
| New | +$690K | ﹤0.01% | 4160 |
|
|
2017
Q1 | – | Sell |
-63,900
| Closed | -$7.37M | – | 7674 |
|
|
2016
Q4 | $7.37M | Hold |
63,900
| – | – | ﹤0.01% | 1754 |
|
|
2016
Q3 | $6.68M | Sell |
63,900
-4,400
| -6% | -$459K | ﹤0.01% | 1755 |
|
|
2016
Q2 | $6.65M | Buy |
+68,300
| New | +$6.45M | ﹤0.01% | 1705 |
|
|
2015
Q1 | – | Sell |
-300
| Closed | -$27K | – | 8876 |
|
|
2014
Q4 | $27K | Buy |
+300
| New | +$25.4K | ﹤0.01% | 7217 |
|
Other funds holding CME
VCM
VPM
UBS Group's CME Position: Q1 2026 in Review
UBS Group increased its CME Group (CME) stake by 7.5% in Q1 2026, buying an estimated $41.8M and bringing the position to 2,022,656 shares worth $597M. The position accounts for 0.09% of the portfolio, ranked #224.
UBS Group first reported a position in CME in Q4 2014 and has held it in 46 quarters since. The position peaked at $805M in Q2 2025. 1,790 funds tracked by Wall St. Rank hold CME as of Q1 2026.
- UBS Group held 2,022,656 shares of CME Group worth $597M as of Q1 2026.
- UBS Group bought 140,840 CME Group shares in Q1 2026, an estimated $41.8M.
- CME Group made up 0.09% of UBS Group's portfolio in Q1 2026, its #224 holding.
- UBS Group first reported a position in CME Group in Q4 2014 and has held it in 46 quarters since.
- UBS Group's CME Group position peaked at $805M in Q2 2025.
- 1,790 funds tracked by Wall St. Rank held CME Group as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.